Two years after emerging from bankruptcy, biomanufacturing specialist Amyris is not yet profitable, but is a “drastically different company” with a burn rate a “fraction of what it was” thanks to tighter operational controls, stronger cash discipline, and a revised business model, says CEO Kathy Fortmann. The synthetic biology pioneer—which was founded in 2003, went public in 2010, and filed for bankruptcy in 2023—had an “overleveraged balance s…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.